[go: up one dir, main page]

MX2017008643A - Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf). - Google Patents

Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).

Info

Publication number
MX2017008643A
MX2017008643A MX2017008643A MX2017008643A MX2017008643A MX 2017008643 A MX2017008643 A MX 2017008643A MX 2017008643 A MX2017008643 A MX 2017008643A MX 2017008643 A MX2017008643 A MX 2017008643A MX 2017008643 A MX2017008643 A MX 2017008643A
Authority
MX
Mexico
Prior art keywords
pdgf
vegf
fusion proteins
fusion protein
binding domain
Prior art date
Application number
MX2017008643A
Other languages
English (en)
Inventor
Zen Kevin
Horng HER Jeng-
Tsu Chen Huang-
Shyang Leou Jiun-
Hsuan Hsu Ching-
Tzu WU Pei-
Original Assignee
Allgenesis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allgenesis Biotherapeutics Inc filed Critical Allgenesis Biotherapeutics Inc
Publication of MX2017008643A publication Critical patent/MX2017008643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)

Abstract

Se describen proteínas de fusión que contienen una porción de unión a PDGF, una porción de unión a VEGF y una región de anticuerpo Fc; también se describen ácidos nucleicos que codifican las proteínas de fusión, composiciones que comprenden las proteínas de fusión y métodos de utilización de las proteínas de fusión para tratar o prevenir condiciones clínicas caracterizadas por angiogénesis anormal, tales como permeabilidad vascular, edema o inflamación.
MX2017008643A 2015-03-11 2016-03-10 Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf). MX2017008643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131261P 2015-03-11 2015-03-11
PCT/US2016/021762 WO2016145189A1 (en) 2015-03-11 2016-03-10 Fusion protein comprising a ligand binding domain of vegf and pdgf

Publications (1)

Publication Number Publication Date
MX2017008643A true MX2017008643A (es) 2018-04-26

Family

ID=55642865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008643A MX2017008643A (es) 2015-03-11 2016-03-10 Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).

Country Status (13)

Country Link
US (1) US11299531B2 (es)
EP (1) EP3268386B1 (es)
JP (1) JP6649393B2 (es)
KR (1) KR20170117107A (es)
CN (1) CN107108757B (es)
AU (1) AU2016229053B2 (es)
BR (1) BR112017014615A2 (es)
CA (1) CA2970384A1 (es)
ES (1) ES2873379T3 (es)
MX (1) MX2017008643A (es)
SG (1) SG11201705271YA (es)
TW (1) TWI675844B (es)
WO (1) WO2016145189A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2797901T3 (es) * 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
US11254722B2 (en) * 2017-02-06 2022-02-22 Academia Sinica Recombinant proteins and uses thereof
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
AU2019227715B2 (en) * 2018-02-28 2022-03-31 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020037309A1 (en) * 2018-08-17 2020-02-20 Trican Biotechnology Co., Ltd. Anti-angiogenesis fusion protein and uses thereof
CN112552410A (zh) * 2019-09-26 2021-03-26 三生国健药业（上海）股份有限公司 一种抗体融合蛋白及其制法和在抗肿瘤中的应用
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN112834753A (zh) * 2019-11-22 2021-05-25 北京泰德制药股份有限公司 一种融合蛋白体外生物学活性的检测方法
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
CN116162148B (zh) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 多特异性配体结合分子及其应用
CN116836281A (zh) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7h3抗体及包含其的双功能抗体
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
SG10201912956YA (en) * 2013-03-13 2020-02-27 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
CN105026433B (zh) * 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
ES2797901T3 (es) * 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis

Also Published As

Publication number Publication date
CN107108757A (zh) 2017-08-29
EP3268386A1 (en) 2018-01-17
JP6649393B2 (ja) 2020-02-19
KR20170117107A (ko) 2017-10-20
US20170369552A1 (en) 2017-12-28
AU2016229053A1 (en) 2017-07-06
ES2873379T3 (es) 2021-11-03
US11299531B2 (en) 2022-04-12
WO2016145189A1 (en) 2016-09-15
SG11201705271YA (en) 2017-07-28
TW201643186A (zh) 2016-12-16
AU2016229053B2 (en) 2018-07-12
EP3268386B1 (en) 2021-03-31
JP2018512120A (ja) 2018-05-17
TWI675844B (zh) 2019-11-01
CA2970384A1 (en) 2016-09-15
CN107108757B (zh) 2021-10-19
BR112017014615A2 (pt) 2018-02-06
WO2016145189A8 (en) 2017-09-08
AU2016229053A8 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2017008643A (es) Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
NZ725568A (en) Modified j-chain
HK1254803A1 (zh) 新型pd -1的免疫调节剂
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EP3486256A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX2018002183A (es) Composiciones y metodos para tratamiento del dolor.
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
HK1254880A1 (zh) 抗pd-1抗体及其应用
MY191944A (en) Binding proteins and methods of use thereof
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
WO2014150877A3 (en) Anti-tau antibodies and methods of use
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA202091567A1 (ru) Химерные белки мти
NZ731491A (en) Cd83 binding proteins and uses thereof
EA201790725A1 (ru) Основанные на близости расположения способы выбора партнеров для связывания
EP3257523A4 (en) Use of polypeptide complex as polypeptide or protein drug carrier, method, and fusion protein complex thereof
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
EP3927327C0 (en) BOTULINUM TOXIN LOCALIZATION DEVICES